MAPK1 and cancer: This mechanism has the additional “advantage” of enlisting parallel survival pathways, such as the PI3K/AKT cascade [116–118,122], whose activation strongly reduces the sensitivity of K-Ras mutant cancer to Erk inhibition [123].